RNS Number : 3093J
Advanced Medical Solutions Grp PLC
27 June 2017
For filings with the FCA include the annex | |||||
For filings with issuer exclude the annex | |||||
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES | |||||
1. Identity of the issuer or the underlying issuer | Advanced Medical Solutions Group plc | ||||
2 Reason for the notification (please tick the appropriate box or boxes): | |||||
An acquisition or disposal of voting rights | ü | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||||
An event changing the breakdown of voting rights | |||||
Other (please specify): | |||||
3. Full name of person(s) subject to the | Octopus Investments Nominees Limited | ||||
4. Full name of shareholder(s) (if different from 3.): | n/a | ||||
5. Date of the transaction and date on | 23/06/2017 | ||||
6. Date on which issuer notified: | 26/06/2017 | ||||
7. Threshold(s) that is/are crossed or | 9% | ||||
8. Notified details:n/a | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type of
if possible using |
Situation previous | Resulting situation after the triggering transaction | ||||||||||||||
Number |
Number |
Number |
Number of voting | % of voting rights | ||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||
GB0004536594 | 19,004,675 | 19,004,675 | 19,256,735 | 19,256,735 | 9.10% | |||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financial | Exercise price | Expiration date |
Exercise/ | Number of voting rights instrument refers to | % of voting rights | |||||||||||
Nominal | Delta | |||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
19,256,735 | 9.10% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the | ||
n/a | ||
Proxy Voting: | ||
10. Name of the proxy holder: | n/a | |
11. Number of voting rights proxy holder will cease to hold: | n/a | |
12. Date on which proxy holder will cease to hold voting rights: | n/a | |
13. Additional information: | ||
14. Contact name: | Daryl O'Brien | |
15. Contact telephone number: | 0203 1400 942 | |
Note: Annex should only be submitted to the FCA not the issuer | |
Annex: Notification of major interests in share | |
A: Identity of the persons or legal entity subject to the notification obligation | |
Full name (including legal form of legal entities) | Peter Orsi |
Contact address (registered office for legal entities) | 33 Holborn, London, EC1N 2HT |
Phone number & email | 020 7710 2877 |
Other useful information (at least legal representative for legal persons) | |
B: Identity of the notifier, if applicable | |
Full name | |
Contact address | |
Phone number & email | |
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) | |
C: Additional information | |
For notes on how to complete form TR-1 please see the FCA website. |
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEAEKXASPXEFF
Advanced Medical Solutions Group plc published this content on 27 June 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 June 2017 13:39:11 UTC.
Original documenthttps://www.admedsol.com/investor-relations/regulatory-news-announcements/3352124-3128/
Public permalinkhttp://www.publicnow.com/view/428E2ABB857986AAD33F85FC9F0DA311A483E132